Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2007

View Archived Issues

New therapeutic agents for neurological disorders reported in recent patents

Novel therapeutic agents for cardiovascular disorders imparted in recent patents

New therapeutics for cancer covered in recent patent literature

Angptl4 validated as a drug target in cardiovascular disorders

PRT-054021 prevents venous thromboembolism after knee replacement

Tolevamer liquid fails to meet primary endpoint in CDAD trial

Roche and Alnylam form alliance in RNAi therapeutics

Bristol-Myers Squibb terminates MIV-170 license agreement with Medivir

Prolonged treatment with amylin mimetic peptide slows gastric emptying and improves glucose control

PTP1B inhibition improves insulin sensitivity via increases in adiponectin in obese monkeys

ProEthic files NDA for PRO-513 for migraine headaches

Silence Therapeutics and AstraZeneca to codevelop siRNA molecules

BHI-001: a novel Hsp90 inhibitor with improved therapeutic index

GW and Otsuka collaborate to research and develop cannabinoids

Clavis Pharma's phase II combination study of Elacyt approved

Positive results for transdermal delivery of hPTH (1-34) in phase I trials

Hsp32 validated as a therapeutic target in systemic mastocytosis

SPA agreement for pivotal study of oral Fodosine in cutaneous T-cell lymphoma

Japanese launch for Nesp

Positive preclinical results of new CRAC channel inhibitor in models of allergic inflammation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
ATNM-400 radioconjugate shows efficacy in resistant breast cancer
BioWorld Science
Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies...